GBM AGILE™ will be a revolutionary new way of conducting clinical trials to test potential brain cancer therapies and deliver better treatments faster than traditional clinical trials.
It is the biggest global collaboration in the history of brain cancer research, backed by more than 200 collaborators around the world.
Traditionally, pharmaceutical companies test one drug at a time and patients can be on trials for up to two years before they know whether the treatment is working or not. Success or failure is only measured at the end and it can take up to 12 years and more than $1.2 billion to get a new treatment to patients.
GBM AGILE™ is an adaptive clinical trial platform, which tests treatments tailored to patients’ genomic profiles using their individual biological and genomic information.
Results will be learned as the trial progresses, and this will allow clinicians to continuously add data and apply those learnings to the next patient who enters the trial.
> that is true agility
As well as testing experimental new therapies, this approach will look at repurposing treatments for use on brain cancer that are already being tested in other diseases, saving years of development time.
We are dedicated to bring this trial to Australia for hundreds of patients to access.
“This is the best opportunity we’ve had to dramatically improve outcomes for people with brain cancer. One of the big problems is that traditional trials leave patients and researchers in the dark for long periods of time about the impact of potential treatments. GBM AGILE™ will change the game completely, with a systematic approach to reveal potential treatments far quicker than has ever been possible”
Our mission is to increase five-year survival to 50% within 10 years. Together, we will succeed.
KZA Price at posting:
66.5¢ Sentiment: Buy Disclosure: Held
